Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Stanford University
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
Following termination of its immuno-oncology partnership with Bristol, Nektar is paring operations, closing its India site and focusing on mid-stage NKTR-358, partnered with Lilly, and NKTR-255.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Stanford Univeristy School of Medicine